Dementia Bulletin.

from Mersey Care Evidence and Library Service.

All credit goes too Mersey Care Evidence and Library Service.

In this issue:

  • Why sleep assessment belongs in the memory clinic
  • Neuropathologic features of cognitively defined Alzheimer’s disease subgroups in the Adult Changes in Thought study
  • Associations Between Biomarkers of Alzheimer’s Disease and Sleep in Cognitively Unimpaired Older Adults
  • Systematic Policy and Evidence Review to Consider How Dementia Education and Training Are Best Delivered in the Social Care Workforce and How Policy Does or Can Enable Its Implementation in England
  • Plus much more

26 October 2026 – Evidently Better

Some articles may require an Open Athens account which you can register for at OpenAthens | Registration

If you have any questions or need help don’t hesitate to get in touch with us at Academic.Library@lscft.nhs.uk

Or come to see us at The Gosall Library | Lantern Centre | Vicarage Lane | Preston | PR2 8DW

US research suggests slowing, not stopping, Alzheimer’s should be the goal for clinical drug trials

Slowing progression of, rather than stopping, Alzheimer’s disease has measurable benefits for patients and families and may be a more realistic goal for clinical drug trials, a new report by the American Alzheimer’s Association has suggested.

The report‘s authors call for a “reframing” of how researchers define “clinically meaningful” in randomized controlled trials, adding that they consider it is time to adjust expectations of outcomes from relatively short clinical trials.

The report was published by an expert work group convened by the Alzheimer’s Association. It was prompted, in part, by the US Food and Drug Administration’s controversial decision to grant aducanumab (Aduhelm) accelerated approval, which came over the objection of an advisory panel that found the drug was ineffective.

Slowing, Not Stopping, Alzheimer’s a Better Goal for Drug Trials? (medscape.com)